Brief: HLS Therapeutics Announces The Sale Of Its Xenpozyme Royalty Interest To DRI Healthcare Trust

DRI Healthcare Trust

02/07/2024 12:09

July 2 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES THE SALE OF ITS XENPOZYME®
ROYALTY
INTEREST TO DRI HEALTHCARE TRUST
    * HLS THERAPEUTICS INC: TOTAL CONSIDERATION OF UP TO $45.75
MILLION
    * HLS THERAPEUTICS INC - TO USE UPFRONT CASH TO PAY DOWN
DEBT
    * HLS THERAPEUTICS INC - LOWERS 2024 ROYALTY REVENUE
GUIDANCE TO
$1.5 TO $1.7 MILLION
    * HLS THERAPEUTICS INC - UPDATES 2024 TOTAL REVENUE GUIDANCE
TO
$58.5 TO $59.7 MILLION

Source text for Eikon:  ID:nCNW4N9h2a 
Further company coverage:  HLS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))